Antibody-mediated radiotherapy

Journal Article · Wed May 01 04:00:00 EDT 1985 · Cancer (Philadelphia); (United States)

DOI:https://doi.org/10.1002/1097-0142(19850501)55:9+<2229::AID-CNCR2820551427>3.0.CO;2-X· OSTI ID:5407606

Bloomer, W D; Lipsztein, R; Dalton, J F

Antibodies that react with antigens on the surface of tumor cells but not normal cells have great potential for cancer detection and therapy. If radiolabeled without loss of immunologic specificity, such antibodies may be able to deliver cytoxic amounts of radiation. Target- cell specificity and a high extraction coefficient are necessary with any radionuclide in order to minimize normal tissue irradiation. Tumor- cell-retention time and the rate of catabolized radionuclide will also influence ultimate applicability. Among the unanswered questions for choosing a radionuclide is the choice of particle emitter. Although classic beta emitters have been used in a number of clinical situations, they have not had a major impact on disease outcome except in diseases of the thyroid. Unfortunately, Auger emitters such as iodine 125 are cytotoxic only when localized within close proximity to the genome. On the other hand, alpha emitters such as astatine 211 eliminate the need for subcellular sequestration but not cell-specific localization. 34 references.

• Research Organization: Mount Sinai Medical Center, New York, NY
• OSTI ID: 5407606
• Journal Information: Cancer (Philadelphia); (United States), Journal Name: Cancer (Philadelphia); (United States) Vol. 55:Suppl. 9; ISSN CANCA
• Country of Publication: United States
• Language: English

Related Subjects

550601 -- Medicine-- Unsealed Radionuclides in Diagnostics
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ALPHA DECAY RADIOISOTOPES
ALPHA PARTICLES
ANIMAL CELLS
ANTIBODIES
ANTIGEN-ANTIBODY REACTIONS
ASTATINE 211
ASTATINE ISOTOPES
BETA DECAY RADIOISOTOPES
BETA PARTICLES
CHARGED PARTICLES
DAYS LIVING RADIOISOTOPES
DIAGNOSIS
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
IMMUNOTHERAPY
INTERMEDIATE MASS NUCLEI
IODINE 125
IODINE ISOTOPES
ISOTOPES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
TUMOR CELLS